158 related articles for article (PubMed ID: 38076413)
41. HbA1c and hypoglycaemia in intensively treated type 2 diabetes: a retrospective cohort study in primary care.
Malawana M; Kerry S; Mathur R; Robson J
JRSM Open; 2018 Jul; 9(7):2054270418773669. PubMed ID: 30013791
[TBL] [Abstract][Full Text] [Related]
42. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
43. Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications.
Frier BM
Nat Rev Endocrinol; 2014 Dec; 10(12):711-22. PubMed ID: 25287289
[TBL] [Abstract][Full Text] [Related]
44. The Experience of Hypoglycaemia and Strategies Used For Its Management by Community-Dwelling Adults with Diabetes Mellitus: A Systematic Review.
Pamela TS; Hui-Chen C; Taylor BJ; Hegney DG
JBI Libr Syst Rev; 2011; 9(50):2063-2104. PubMed ID: 27820436
[TBL] [Abstract][Full Text] [Related]
45. Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes.
Owens DR; Bolli GB; Charbonnel B; Haak T; Landgraf W; Porcellati F; Traylor L; Kautzky-Willer A
Diabetes Obes Metab; 2017 Nov; 19(11):1546-1554. PubMed ID: 28449412
[TBL] [Abstract][Full Text] [Related]
46. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies.
Riddle MC; Vlajnic A; Zhou R; Rosenstock J
Diabetes Obes Metab; 2013 Sep; 15(9):819-25. PubMed ID: 23489438
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of the Flexible Lifestyles Empowering Change intervention on metabolic and psychosocial outcomes in adolescents with type 1 diabetes (FLEX): a randomised controlled trial.
Mayer-Davis EJ; Maahs DM; Seid M; Crandell J; Bishop FK; Driscoll KA; Hunter CM; Kichler JC; Standiford D; Thomas JM;
Lancet Child Adolesc Health; 2018 Sep; 2(9):635-646. PubMed ID: 30119757
[TBL] [Abstract][Full Text] [Related]
48. Improved glycemic control in veterans with poorly controlled diabetes mellitus using a Specialty Care Access Network-Extension for Community Healthcare Outcomes model at primary care clinics.
Watts SA; Roush L; Julius M; Sood A
J Telemed Telecare; 2016 Jun; 22(4):221-4. PubMed ID: 26253745
[TBL] [Abstract][Full Text] [Related]
49. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial.
Heller S; White D; Lee E; Lawton J; Pollard D; Waugh N; Amiel S; Barnard K; Beckwith A; Brennan A; Campbell M; Cooper C; Dimairo M; Dixon S; Elliott J; Evans M; Green F; Hackney G; Hammond P; Hallowell N; Jaap A; Kennon B; Kirkham J; Lindsay R; Mansell P; Papaioannou D; Rankin D; Royle P; Smithson WH; Taylor C
Health Technol Assess; 2017 Apr; 21(20):1-278. PubMed ID: 28440211
[TBL] [Abstract][Full Text] [Related]
50. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration.
UK Hypoglycaemia Study Group
Diabetologia; 2007 Jun; 50(6):1140-7. PubMed ID: 17415551
[TBL] [Abstract][Full Text] [Related]
51. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
Fullerton B; Jeitler K; Seitz M; Horvath K; Berghold A; Siebenhofer A
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD009122. PubMed ID: 24526393
[TBL] [Abstract][Full Text] [Related]
52. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
[TBL] [Abstract][Full Text] [Related]
53. A study to assess the unmet medical needs associated with the use of basal insulin in patients with type 2 diabetes.
Frechtel G; Forti L; Faingold C; Perez Mangui F; Orio S; Issa C; Guaita MS; Vivas N; De Luca JA
Endocrinol Diabetes Metab; 2021 Jan; 4(1):e00164. PubMed ID: 33532606
[TBL] [Abstract][Full Text] [Related]
54. Deintensification of Diabetes Medications among Veterans at the End of Life in VA Nursing Homes.
Niznik JD; Hunnicutt JN; Zhao X; Mor MK; Sileanu F; Aspinall SL; Springer SP; Ersek MJ; Gellad WF; Schleiden LJ; Hanlon JT; Thorpe JM; Thorpe CT
J Am Geriatr Soc; 2020 Apr; 68(4):736-745. PubMed ID: 32065387
[TBL] [Abstract][Full Text] [Related]
55. Continuous Subcutaneous Insulin Infusion (CSII) Pumps for Type 1 and Type 2 Adult Diabetic Populations: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(20):1-58. PubMed ID: 23074525
[TBL] [Abstract][Full Text] [Related]
56. Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.
Signorovitch JE; Macaulay D; Diener M; Yan Y; Wu EQ; Gruenberger JB; Frier BM
Diabetes Obes Metab; 2013 Apr; 15(4):335-41. PubMed ID: 23121373
[TBL] [Abstract][Full Text] [Related]
57. De-Intensification Of Blood Glucose Lowering Medication In People Identified As Being Over-Treated: A Mixed Methods Study.
Hart HE; Ditzel K; Rutten GE; de Groot E; Seidu S; Khunti K; Vos RC
Patient Prefer Adherence; 2019; 13():1775-1783. PubMed ID: 31695339
[TBL] [Abstract][Full Text] [Related]
58. Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.
Davies MJ; Russell-Jones D; Selam JL; Bailey TS; Kerényi Z; Luo J; Bue-Valleskey J; Iványi T; Hartman ML; Jacobson JG; Jacober SJ;
Diabetes Obes Metab; 2016 Nov; 18(11):1055-1064. PubMed ID: 27349219
[TBL] [Abstract][Full Text] [Related]
59. Less severe hypoglycaemia, better metabolic control, and improved quality of life in Type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years.
Linkeschova R; Raoul M; Bott U; Berger M; Spraul M
Diabet Med; 2002 Sep; 19(9):746-51. PubMed ID: 12207811
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
